D-dimer levels < 250 ng/mL after oral anticoagulation predicted a low risk for recurrent venous thromboembolism

March 2004
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p50
Academic Journal
The article examines the association of levels of D-dimer, measured after withdrawal of oral anticoagulant therapy (OAT), with risk for recurrent venous thromboembolism (VTE) in patients who have had a first unprovoked VTE. 610 patients more than 18 years of age with a first unprovoked, objectively documented VTE who received OAT for more than 3 months. It was found that the rate of VTE recurrence was lower in patients with D-dimer levels less 250 ng/mL than in those with D-dimer levels less than 250 ng/mL.


Related Articles

  • Single drug regimen for treatment of acute venous thromboembolism in oncology patients. Khajuria, Ankur // British Journal of Hospital Medicine (17508460);Mar2014, Vol. 75 Issue 3, p176 

    A letter to the editor in response to the article "Apixaban for extended treatment of venous thromboembolism," by G. Agnelli and colleagues in the 2013 issue of the "New England Journal of Medicine" is presented.

  • Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians. Nay Min Tun; Thein Hlaing Oo // Thrombosis;2013, p1 

    Traditional anticoagulants, such as warfarin and enoxaparin, have several limitations, including parenteral administration, need for laboratory monitoring, and ongoing dose adjustment, whichmay limit optimal patient care. Newer oral anticoagulants, such as direct thrombin inhibitors (e.g.,...

  • Validity of self-reported regimen of dose by patient initiating warfarin treatment from a prospective cohort. Dumas, S.; Rouleau-Mailloux, E.; Bardhadi, A.; Tardif, J.-C.; Talajic, M.; Dubé, M.-P.; Perreault, S. // Journal of Population Therapeutics & Clinical Pharmacology;2014, Vol. 21 Issue 1, pe132 

    Introduction: Warfarin is a widely prescribed oral anticoagulant with a narrow therapeutic index. In observational studies, errors in measurement of the dose of warfarin can lead to a major misclassification bias. Aims: To evaluate the validity of the dose of warfarin as reported by the patient...

  • Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism. Knepper, J.; Ramacciotti, E.; Wakefield, T. W. // Phlebology;Feb2011, Vol. 26 Issue 1, p3 

    Traditional therapeutic oral anticoagulation strategies often require invasive dosing or monitoring. Vitamin K antagonists (VKAs) have a large number of interactions, delayed onset requires frequent dose monitoring, and they have a small margin between therapeutic dose and bleeding...

  • Can D-dimer Establish Best Duration of Anti-coagulation?  // Primary Care Reports;Jan2007, Vol. 13 Issue 1, p2 

    The article discusses research being done on the duration of anticoagulation in patients with normal D-dimer level. It references a study by S. L. Wolf et al, published in the 2006 issue of "Journal of American Medical Association." The research reveals the rate of thromboembolitic event in...

  • Review: D-dimer concentrations predict risk of recurrent VTE after anticoagulant therapy is stopped. Douketis, J. D. // Evidence Based Medicine;Apr2009, Vol. 14 Issue 2, p59 

    The article discusses the risk of recurrent venous thromboembolism (VTE) due to D-dimer concentrations after the surcease of anticoagulant therapy of the patients in the U.S. The study measures the D-dimer concentrations of the patients for 3 weeks to 2 months after anticoagulant therapy was...

  • Rivaroxaban: Another Warfarin Replacement.  // Clinical Cardiology Alert;Jan2011 Pharamacology, p1 

    No abstract available.

  • Concept of a point of care test to detect new oral anticoagulants in urine samples. Harenberg, Job; Krämer, Sandra; Du, Shanshan; Weiss, Christel; Krämer, Roland // Thrombosis Journal;2013, Vol. 11 Issue 1, p15 

    New oral anticoagulants (NOAC) are approved for several indications for prophylaxis and treatment of venous thromboembolism and for prevention of embolism in atrial fibrillation at fixed daily doses without need of laboratory guided dose adjustment. Due to their low molecular weight of about 500...

  • Anticoagulation for Prosthetic Valves. Kaneko, Tsuyoshi; Aranki, Sary F. // Thrombosis;2013, p1 

    Implantation of prosthetic valve requires consideration for anticoagulation. The current guideline recommends warfarin on all mechanical valves. Dabigatran is the newgeneration anticoagulation medication which is taken orally and does not require frequent monitoring. This drug is approved for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics